Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Published in: Advances in Therapy 3/2012

01-03-2012 | Review

Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma

Authors: Sergio Vázquez, Luis León, Ovidio Fernández, Martín Lázaro, Enrique Grande, Luis Aparicio

Published in: Advances in Therapy | Issue 3/2012

Login to get access
Metadata
Title
Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
Authors
Sergio Vázquez
Luis León
Ovidio Fernández
Martín Lázaro
Enrique Grande
Luis Aparicio
Publication date
01-03-2012
Publisher
Springer Healthcare Communications
Published in
Advances in Therapy / Issue 3/2012
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-011-0099-9

Other articles of this Issue 3/2012

Advances in Therapy 3/2012 Go to the issue

Review

Apixaban: an Oral Direct Factor-Xa Inhibitor

Original Research

Phase 2 Study of Modified Irinotecan and Bolus 5-Fluorouracil/l-Leucovorin in Japanese Metastatic Colorectal Cancer Patients

Original Research

Contribution of Endermology to Improving Indurations and Panniculitis/Lipoatrophy at Glatiramer Acetate Injection Site

Original Research

Exploring Channeling Optimized Radiofrequency Energy: a Review of Radiofrequency History and Applications in Esthetic Fields

Review

Dipeptidyl Peptidase-4 Inhibitors in the Elderly: More Benefits or Risks?

Original Research

Cost per Treated Patient for Etanercept, Adalimumab, and Infliximab Across Adult Indications: a Claims Analysis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits